Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

CytRx Corporation CYTR

Sector: Healthcare | Sub-Sector: Biotechnology

CytRx Corp is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib.
Price: $3.60 | Change: +$0.08 | %Change: +2.27%
Volume: 1.0m | Day High/Low: 3.75/3.46 | 52 Week High/Low: 8.35/2.00


View modes: 
0 stars

CYTR and ICLD have same lies from blog seekingalpha

Just to advise you that CYTR and ICLD have exactly the same lawsuits being filed against them and all stemming from the blogger seekingalpha.com. Exactly the same law firms are involved in both...read more
0 stars

CytRx Corp.’s (CYTR) Aldoxorubicin Demonstrates Blockbuster

CytRx Corp.’s (CYTR) Aldoxorubicin Demonstrates Blockbuster Potential, Says Motley Fool Contributor CytRx is a biopharmaceutical R&D company particularly focused on the clinical development of...read more
0 stars

CytRx Corp. (CYTR) Presenting at the 16th Annual BIO CEO & I

CytRx Corp. (CYTR) Presenting at the 16th Annual BIO CEO & Investor Conference CytRx today released a news release stating it will be presenting at the 16th Annual BIO CEO & Investor Conference next...read more
0 stars

CytRx Corp. (CYTR) Announces Pricing of $75M Public of Commo

CytRx Corp. (CYTR) Announces Pricing of $75M Public of Common Stock at $6.50 per Share CytRx, a biopharmaceutical research and development company specializing in oncology, today issued a news...read more
0 stars

CytRx Corp.’s (CYTR) Aldoxorubicin Shows Potential for Exten

CytRx Corp.’s (CYTR) Aldoxorubicin Shows Potential for Extended Application in Field of Cancer Treatment There are more than 100 different cancer diseases. Cancer is the leading cause of death in the...read more
0 stars

CytRx Corp. (CYTR) Commences Phase 2 Clinical Trial with Ald

CytRx Corp. (CYTR) Commences Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposi’s Sarcoma Today before the opening bell, CytRx Corp., a biopharmaceutical...read more
0 stars

CytRx Corp. (CYTR) Reports FDA Approval to Extend Aldoxorubi

CytRx Corp. (CYTR) Reports FDA Approval to Extend Aldoxorubicin Dosing Cycles in Upcoming Pivotal, Global Phase 3 Trial for Soft Tissue Sarcomas CytRx Corp., a biopharmaceutical research and...read more
0 stars

6 Primary Reasons This Seeking Alpha Contributor is Bullish

6 Primary Reasons This Seeking Alpha Contributor is Bullish about CytRx Corp. (CYTR) In a recent article entitled “Spotlight 2014-Biotech CytRx Corporation,” Seeking Alpha contributing writer The...read more
0 stars

CytRx Corp. (CYTR) Featured in Exclusive Interview with Miss

CytRx Corp. (CYTR) Featured in Exclusive Interview with MissionIR MissionIR today released its interview with CytRx Corp. President and Chief Executive Officer Steven Kriegsman, as well as the...read more
0 stars

CytRx Corp. (CYTR) Appoints Shanta Chawla, M.D. as Vice Pres

CytRx Corp. (CYTR) Appoints Shanta Chawla, M.D. as Vice President of Clinical Development Today before the opening bell, CytRx reported that it has appointed Dr. Shanta Chawla as its Vice President...read more
0 stars

CytRx Corp. (CYTR) Doses First Patient in Phase 2 Clinical T

CytRx Corp. (CYTR) Doses First Patient in Phase 2 Clinical Trial with Aldoxorubicin CytRx just announced substantial progress in its therapeutic agent aldoxorubicin’s phase 2 clinical trial for...read more
0 stars

CytRx Corp. (CYTR) Continues Positive Trajectory, Says Wall

CytRx Corp. (CYTR) Continues Positive Trajectory, Says Wall St. Cheat Sheet Contributor Biotech small-cap CytRx is getting a lot of attention lately – stemming from positive top-line results of its...read more
0 stars

CytRx Corp. (CYTR) Massive Potential of Aldoxorubicin in Mul

CytRx Corp. (CYTR) Massive Potential of Aldoxorubicin in Multiple Soft Tissue Sarcomas Clear from Recent Clinical Data CytRx has really been turning heads on the street since the company’s lead...read more
0 stars

CytRx Corp. (CYTR) Data Confirm Top-Line Efficacy Results of

CytRx Corp. (CYTR) Data Confirm Top-Line Efficacy Results of Phase 2b Clinical Trial for Cancer Drug CytRx today reports that additional statistical analyses further support the company’s previously...read more
0 stars

CytRx Corp. (CYTR) Potential Emphasized in Seeking Alpha Art

CytRx Corp. (CYTR) Potential Emphasized in Seeking Alpha Article CytRx, a biopharm research and development company specializing in cancer treatment, was recently featured in an article by Seeking...read more
0 stars

CytRx Corp. (CYTR) Featured on Forbes.com for Aldoxorubicin’

CytRx Corp. (CYTR) Featured on Forbes.com for Aldoxorubicin’s Potential as Treatment for Brain Cancer In a recent review published on Forbes.com, contributor Tom Meyer highlights four biotech...read more
0 stars

CytRx Corp. (CYTR) Featured in Bullish Seeking Alpha Article

CytRx Corp. (CYTR) Featured in Bullish Seeking Alpha Article CytRx, a biopharm research and development company specializing in the development of drug candidates for the field of oncology, was...read more
0 stars

Wall Street Cheat Sheet Contributor Corrects Allegedly “Inac

Wall Street Cheat Sheet Contributor Corrects Allegedly “Inaccurate” CytRx Corp. (CYTR) Article Shares of biotech company CytRx saw gains of 150 percent from December 9-December 13, fueled by positive...read more
0 stars

CytRx Corp. (CYTR) Price Rally, Potential Mirrors Pharmacycl

CytRx Corp. (CYTR) Price Rally, Potential Mirrors Pharmacyclics (PCYC) Performance It’s quite a catching opener, especially if you’re an investor with an interest in the biotech sector. It’s also a...read more
0 stars

CytRx, Inc. (CYTR) Reports Statistically Significant Results

CytRx, Inc. (CYTR) Reports Statistically Significant Results from Aldoxorubicin Phase 2b CytRx, an biopharmaceutical innovator of oncology treatments, today announced extremely promising results in...read more